[{"address1": "The Omeros Building", "address2": "201 Elliott Avenue West", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 676 5000", "website": "https://www.omeros.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 198, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gregory A. Demopulos M.D.", "age": 65, "title": "Co-Founder, Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 5965279, "exercisedValue": 0, "unexercisedValue": 39325}, {"maxAge": 1, "name": "Mr. Peter B. Cancelmo J.D.", "age": 45, "title": "VP, General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 611435, "exercisedValue": 0, "unexercisedValue": 5500}, {"maxAge": 1, "name": "Dr. Pamela Pierce Palmer M.D., Ph.D.", "age": 61, "title": "Co-Founder", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David J. Borges", "age": 60, "title": "VP of Finance, Chief Accounting Officer & Treasurer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. George A. Gaitanaris M.D., Ph.D.", "age": 67, "title": "Chief Scientific Officer & VP of Science", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter W. Williams", "age": 56, "title": "Vice President of Human Resources", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Catherine A. Melfi Ph.D.", "age": 65, "title": "Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nadia  Dac", "age": 54, "title": "VP & Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Grauer M.D.", "age": 63, "title": "VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David W. Ghesquiere", "age": 57, "title": "Chief Business Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 5, "overallRisk": 9, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.52, "open": 8.49, "dayLow": 8.21, "dayHigh": 8.7, "regularMarketPreviousClose": 8.52, "regularMarketOpen": 8.49, "regularMarketDayLow": 8.21, "regularMarketDayHigh": 8.7, "payoutRatio": 0.0, "beta": 1.98, "forwardPE": -3.5940173, "volume": 601158, "regularMarketVolume": 601158, "averageVolume": 730661, "averageVolume10days": 539010, "averageDailyVolume10Day": 539010, "bid": 6.2, "ask": 10.58, "bidSize": 2, "askSize": 2, "marketCap": 487357824, "fiftyTwoWeekLow": 2.61, "fiftyTwoWeekHigh": 13.6, "fiftyDayAverage": 9.1784, "twoHundredDayAverage": 5.9295, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 797644480, "profitMargins": 0.0, "floatShares": 55373893, "sharesOutstanding": 57949800, "sharesShort": 9451266, "sharesShortPriorMonth": 9273851, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.16309999, "heldPercentInsiders": 0.04467, "heldPercentInstitutions": 0.46126997, "shortRatio": 20.9, "shortPercentOfFloat": 0.1706, "impliedSharesOutstanding": 57949800, "bookValue": -2.66, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -185375008, "trailingEps": -3.14, "forwardEps": -2.34, "enterpriseToEbitda": -4.624, "52WeekChange": 0.91891897, "SandP52WeekChange": 0.14239466, "quoteType": "EQUITY", "currentPrice": 8.41, "targetHighPrice": 36.0, "targetLowPrice": 36.0, "targetMeanPrice": 36.0, "targetMedianPrice": 36.0, "recommendationMean": 2.33333, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 123157000, "totalCashPerShare": 2.125, "ebitda": -172508992, "totalDebt": 433444000, "quickRatio": 2.329, "currentRatio": 2.965, "returnOnAssets": -0.26872998, "grossProfits": -69779000, "freeCashflow": -125302496, "operatingCashflow": -154648000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "OMER", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1740783077, "regularMarketTime": 1740776401, "exchange": "NGM", "messageBoardId": "finmb_32388", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -1.2910869, "regularMarketPrice": 8.41, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1255008600000, "postMarketChangePercent": 0.0, "postMarketPrice": 8.41, "postMarketChange": 0.0, "regularMarketChange": -0.11000061, "regularMarketDayRange": "8.21 - 8.7", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 730661, "fiftyTwoWeekLowChange": 5.8, "fiftyTwoWeekLowChangePercent": 2.2222223, "fiftyTwoWeekRange": "2.61 - 13.6", "fiftyTwoWeekHighChange": -5.1900005, "fiftyTwoWeekHighChangePercent": -0.38161767, "fiftyTwoWeekChangePercent": 91.8919, "earningsTimestampStart": 1743418740, "earningsTimestampEnd": 1743768000, "earningsCallTimestampStart": 1731533400, "earningsCallTimestampEnd": 1731533400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.14, "epsForward": -2.34, "epsCurrentYear": -2.98333, "priceEpsCurrentYear": -2.8189974, "fiftyDayAverageChange": -0.7684002, "fiftyDayAverageChangePercent": -0.083718315, "twoHundredDayAverageChange": 2.4804997, "twoHundredDayAverageChangePercent": 0.418332, "priceToBook": -3.161654, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "shortName": "Omeros Corporation", "longName": "Omeros Corporation", "displayName": "Omeros", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]